**Name of journal: *World Journal of Biological Chemistry***

**ESPS Manuscript NO: 11665**

**Columns: Original Articles**

**Identification of host miRNAs that may limit human rhinovirus replication**

Bondanese VP *et al*. HRV and microRNAs

Victor Paky Bondanese, Ana Francisco-Garcia, Nicole Bedke, Donna E Davies, Tilman Sanchez-Elsner

**Victor Paky Bondanese**, LGL, LabEx LIO, ENS Lyon, Site Monod, 69364 Lyon, France

**Victor Paky Bondanese**, **Ana Francisco-Garcia, Nicole Bedke, Donna E Davies, Tilman Sanchez-Elsner,** Academic Unit of Clinical and Experimental Sciences, University of Southampton Faculty of Medicine, University Hospital Southampton, Southampton SO16 6YD, United Kingdom

**Nicole Bedke**, Immunocore Limited, Milton Park, Abingdon, Oxon OX14 4RY, United Kingdom

**Author contributions:** Bondanese VP and Francisco-Garcia A contributed equally to this work, they performed all the experiments and analyzed the data; Bedke N provided essential reagents; Sanchez-Elsner T and Davies ED conceived the study; Bondanese VP, Sanchez-Elsner T and Davies ED designed the experiments and wrote the manuscript; all authors contributed to the interpretation of the data, revised the manuscript and approved its final form.

**Supported by** MRC, AAIR and the Roger Brooke charitable trust

**Correspondence to:** **Dr. Tilman Sanchez-Elsner, PhD, Senior Lecturer** in Biomedical Sciences, Academic Unit of Clinical and Experimental Sciences, University of Southampton, Faculty of Medicine, Southampton General Hospital, Tremona Road, Southampton SO16 6YD, United Kingdom. [t.sanchez-elsner@soton.ac.uk](mailto:t.sanchez-elsner@soton.ac.uk)

**Telephone:** +44-23-80794410 **Fax:** +44-23-81201761

**Received:** May 29, 2014 **Revised:** September 9, 2014

**Accepted:** October 1, 2014

**Published online:**

**Abstract**

**AIM:** To test whether the replication of human rhinovirus (HRV) is regulated by microRNAs in human bronchial epithelial cells.

**METHODS:** For the present study, the human cell line BEAS-2B (derived from normal human bronchial epithelial cells) was adopted. DICER knock-down, by siRNA transfection in BEAS-2B cells, was performed in order to inhibit microRNA maturation globally. Alternatively, antisense oligonucleotides (anti-miRs) were transfected to inhibit the activity of specific microRNAs. Cells were infected with HRV-1B. Viral replication was assessed by measuring the genomic viral RNA by RT-qPCR. Association between microRNA-induced-silencing-complex and viral RNA was detected by Ago2 co-immunoprecipitation followed by RT-qPCR. Targetscan v.6 was used to predict microRNA target sites on several HRV strains.

**RESULTS:** Here, we show that microRNAs affect replication of HRV-1B. DICER knock-down significantly reduced the expression of mature microRNAs in a bronchial epithelial cell line (BEAS-2B) and in turn, increased the synthesis of HRV-1B RNA. Additionally, HRV-1B RNA co-immunoprecipitated with AGO2 protein, an important effector for microRNA activity suggesting that microRNAs bind to viral RNA during infection. In order to identify specific microRNAs involved in this interaction, we employed bioinformatics analysis, and selected a group of microRNAs that have been reported to be under-expressed in asthmatic bronchial epithelial cells and were predicted to target different strains of rhinoviruses (HRV-1B, -16, -14, -27). Our results suggest that, out of this group of microRNAs, miR-128 and miR-155 contribute to the innate defense against HRV-1B: transfection of specific anti-miRs increased viral replication, as anticipated *in-silico*.

**CONCLUSION:** Taken together, our results suggest that pathological changes in microRNA expression, as already reported for asthma or chronic obstructive pulmonary disease have the potential to affect Rhinovirus replication and therefore may play a role in virus-induced exacerbations.

© 2014 Baishideng Publishing Group Inc. All rights reserved.

**Key words:** Human Rhinovirus; MicroRNAs; MiR-155; SiRNA; Lentiviral transduction; Antiviral innate immunity

**Core tip:** Our results show for the first time that: (1) DICER knock-down increases HRV-1B replication in human bronchial epithelial cells; (2) the genomic RNA of human rhinovirus (HRV)-1B interacts directly with the miRISC during infection; and (3) inhibition of two microRNAs predicted to target HRV-1B, *i.e.,* miR-128 and miR-155, favors viral replication. This supports a role for cellular microRNAs in the antiviral response to HRV-1B mounted by bronchial epithelial cells, and suggests that pathological microRNA dysregulation may contribute to the poor antiviral immunity in diseases such as asthma and chronic obstructive pulmonary disease.

Bondanese VP, Francisco-Garcia A, Bedke N, Davies DE, Sanchez-Elsner T. Identification of host miRNAs that may limit human rhinovirus replication. *World J Biol Chem* 2014; In press

**INTRODUCTION**

MicroRNAs (or miRs) are small, non-coding RNAs that regulate gene expression at the post-transcriptional level. MicroRNAs are synthesized in the nucleus as long primary transcripts. These undergo a complex maturation process that includes cleavage by DICER in the cytoplasm, yielding the single-stranded mature form[1]. Mature microRNAs then associate with Argonaute (AGO) proteins[2]. These constitute the core of the effector complex often referred to as microRNA-induced silencing complex (miRISC)[3]. MicroRNAs modulate the rate of translation and the stability of target mRNAs by binding to partially complementary sites, within the 3’ untranslated region (UTR) of their targets. Not requiring a perfect match, microRNAs of a given sequence can interact with many different mRNAs and therefore, the expression of several genes can be modulated by a single microRNA[4]. It is not straightforward to predict which genes can be regulated by a specific microRNA thus complex algorithms such as Targetscan[5] have been developed for this purpose.

Being part of the mechanisms that cells use to regulate and fine tune gene expression, it is not surprising that microRNAs play a role in many different biological processes such as development, cellular differentiation, maturation or apoptosis, highlighting their importance for normal cell function. As a consequence, their deregulation perturbs gene expression and can have pathological consequences, as evidenced by their involvement in cancer[6]. DICER is essential for mouse embryonic development[7] and later on for correct lung epithelium morphogenesis[8]. MicroRNA expression is highly regulated during lung development[9] in both mouse and human, suggesting an important role during this process[10]. Also in culture, the microRNA profile changes considerably during human bronchial epithelial cell differentiation, controlling the expression of genes involved in this process[11]. Several are the examples of microRNAs involved in the regulation of the immune response. For instance, miR-155 deficient mice showed impaired immune responses in addition to lungs with evident airway remodelling[12]. Importantly, the expression of microRNAs is not regulated only during development but also by a variety of extracellular stimuli such as cytokines, pathogen components and infection. For example, bacterial lipopolysaccharide (LPS) causes up-regulation of miR-155[13] but down-regulation of miR-125b in murine macrophages[14]. As expected by their opposite regulation, the two microRNAs have opposite effects on the expression of TNF-alpha, which is secreted after LPS treatment. Often microRNAs are used by cells to fine tune or reinforce their responses, by targeting signalling molecules. For instance, in monocytes and macrophages, IL-1beta, TNF-alpha and LPS have been shown to up-regulate miR-146a/b. Perhaps in order to prevent excessive inflammation, the microRNA inhibits the expression of IL-1 receptor-associated kinase 1 and 2 (IRAK1 and 2) and TNF receptor-associated factor 6 (TRAF6) which are important signalling proteins of innate immunity pathways[15]. Also vesicular stomatitis virus (VSV) or Influenza A infection up-regulates miR-146a/b with the effect of promoting replication of the virus[16,17]. Respiratory syncytial virus (RSV) can alter cellular microRNA expression[18,19]. In particular, in human bronchial epithelial cells the down-regulation of miR-221 favours viral replication by counteracting the induction of apoptosis in infected cells[20].

In addition to acting on host mRNAs, microRNAs can directly bind and regulate viral RNA and therefore hamper viral replication. Interestingly, such direct antiviral function has been conserved from plants to mammals[21]. In humans, antiviral microRNAs have been shown to act both independently and as important effectors of the interferon (IFN) system, which is paramount in innate antiviral immunity. For instance, HCV (Hepatits C Virus) exemplifies how microRNAs can influence viral tissue tropism and work either in favour or against viruses. In fact, miR-122, a liver-specific microRNA is able to facilitate HCV replication[22]. Conversely, IFN-beta down-regulates miR-122 while up-regulating the expression of other microRNAs with sequence-specific antiviral activity[23]. Recently, IFN-beta treatment of HeLa cells was shown to induce the expression of miR-23b[24] which in turn was able to limit HRV-1B replication, by reducing the levels of the very low-density lipoprotein receptor (VLDLR). DICER-deficient murine macrophages were also more permissive to VSV than wild type cells, with no difference in type I IFN production[25]. DICER and several microRNAs interfere also with the replication of Influenza A virus[26–28] and retroviruses such as HIV-1 (Human Immune Deficiency Virus-1)[29] and PFV-1 (Primate Foamy Virus-1)[30].

Considering the many examples of antiviral microRNAs reported, we hypothesized that Human Rhinoviruses (HRV) are targeted by microRNAs. While responsible for most of the common colds in healthy subjects, HRVs are a major trigger of chronic obstructive pulmonary disease (COPD) and asthma exacerbations[31–33] which represent a significant problem for disease management. HRVs predominantly infect epithelial cells of the upper and lower airways[34–37]. They are non-enveloped viruses of the Picornaviridae family, and are subdivided in three species (A, B and C) based on sequence homology. HRV-A and -B comprise approximately 100 different strains which are also divided into two groups depending on receptor usage. Rhinoviruses of the major subgroup, such as HRV-16, use the intercellular adhesion molecule 1 (ICAM-1) for entry[38] while the low-density lipoprotein receptor (LDLR) family[39] is used by members of the minor subgroup, such as HRV-1B. Shortly after entry, the single stranded genomic RNA functions as mRNA, driving the expression of a single open reading frame that encodes all viral proteins. The double-stranded RNA, that forms during viral replication, is detected by cellular receptors such as Toll-like Receptor 3 (TLR3) and the RNA helicases RIG-I (retinoic acid inducible gene) and MDA5 (melanoma differentiation associated gene-5)[40] leading to the induction of IFNs (and downstream IFN-regulated genes) and pro-inflammatory cytokines[41].

A bioinformatics study suggested that human microRNAs may effectively bind to the genome of Rhinoviruses[42] and artificial siRNAs have been shown to inhibit HRV-16 replication[43]. Here we show that microRNAs in general may be involved in the defence against Rhinovirus in human bronchial epithelial cells and that the inhibition of two microRNAs predicted to target HRV-1B, miR-128 and miR-155, increased the accumulation of intracellular viral RNA. To our knowledge, this is the first experimental study to provide evidence suggesting that constitutively expressed cellular microRNAs regulate HRV replication.

**MATERIALS AND METHODS**

***Cell culture***

BEAS-2B and THP-1 cells were grown in RPMI medium supplemented with Glutamax I (GIBCO) and 10% heat inactivated foetal bovine serum (FBS, GIBCO). All cells were cultured at 37°C in a humified 5% CO2 incubator. For the infection experiments, RPMI with Glutamax I supplemented with 2% FBS was used.

***Propagation of HRV-1B and infection experiments***

HRV-1B was a gift from Professor Sebastian L. Johnston (Imperial College, London). HRV-1B was grown on Ohio HeLa cells (obtained from the American Type Culture Collection) grown in Dulbecco’s Modified Eagles Medium (DMEM, Gibco) supplemented with 10% FBS, 50 IU/mL penicillin, 50 mg/mL streptomycin, 2 mmol/L L‑glutamine. Briefly, HeLa cells were grown up to around 70%-80% confluency. Cells were washed once with HBSS (GIBCO) and then HRV was added. The cell culture vessel was then kept at room temperature on a plate rocker for 1 h. Subsequently, more infection medium was added and finally the cell culture vessel was incubated at 33 °C (in a humidified incubator, in air with 5% CO2) for 16-24 h. After performing three cycles of freeze-thaw at -80 °C, the supernatant (containing the virus) was recovered, cell debris were removed by centrifugation at 800 × g at 4 °C and used to inoculate more HeLa cells. Finally, the virus-containing medium was centrifuged at 800 × g at 4 °C and then filtered through a 0.2 mm syringe filter. All the infection experiments presented here were performed with the same viral stock. The latter was titrated to 5.5 × 106 viral particles/mL by 50% tissue culture infective dose (TCID50) as previously described[44].

For infection experiments, BEAS-2B cells were grown until about 80% confluent, detached by trypsin treatment and seeded at 0.75 × 105 cells/well in 24-well plates. Twenty four hours later, growth medium was replaced with infection medium for about 16 h before infection with HRV-1B. In each experiment, before infection, the cells present in two wells were counted using an improved Neubauer 0.1 mm haemocytometer. Cells were detached by trypsin treatment and re-suspended in 1mL/well. The cell count obtained was used to calculate the volume of viral stock necessary for the desired multiplicity of infection (MOI) according to the following formula: mL of viral stock = (MOI × number of cells)/TCID50. Cells to be infected were first washed with 1mL/well of PBS and then 0.2 mL/well of the viral suspension were added. Cells were then incubated at room temperature on a plate rocker for one hour. At this point, residual virus was removed and cells were washed as above. Then, either 0.5 mL/well of infection medium was added, or cells were harvested (0 h post-infection) using 0.5 mL/well of TRI-Reagent (Ambion). Plates were placed in the incubator for the indicated time, before collection in TRI-Reagent.

***Transfections***

Negative control siRNA and an anti-DICER siRNA were purchased from Ambion (Silencer® Select Validated siRNA). Anti-DICER (Ambion siRNA ID: s23754) sense strand sequence (5’-3’ sequence): GAUCCUAUGUUCAAUCUAAtt. Antisense strand sequence (5’-3’ sequence): UUAGAUUGAACAUAGGAUCga. Negative control #2 (Ambion siRNA ID: 4390846) sequence not provided.

BEAS-2B cells were seeded at 0.75 × 105 cells/well in 24-well plates. Twenty four hours later cells were transfected as follows. Two hundred μL/well of growth medium; for each well to be transfected, 1.5 μL of Oligofectamine (Invitrogen) were diluted in 10 μL of plain RPMI and mixed by pipetting. In a separate microcentrifuge tube, 0.15 μL of 50 μmol/L siRNA were diluted in 40 μL of plain RPMI medium and mixed by pipetting. The tubes were left at room temperature. After 5 min, the contents of the two tubes were mixed together by pipetting and left at room temperature. Twenty minutes later, the mixture was mixed again by pipetting and dispensed on the cells (50 μL/well giving a final siRNA concentration of 30 nmol/L). The following day, the medium present in the wells was replaced with fresh infection medium. BEAS-2B cells were transfected every 36 h (3 d) following the protocol described. This required that 48 h post-transfection cells were detached by trypsin treatment and seeded at the density specified earlier. One day after the last transfection, the medium was replaced with infection medium. Cells were then infected with HRV-1B 24 h later (48 h after the third transfection).

All the anti-miRs (Anti-miR™ miRNA Inhibitors) were purchased from Ambion: anti-miR negative control#1 cat.n: AM17010; anti-hsa-miR-18a, cat.n: AM12973; anti-hsa-miR-19b, cat.n: AM10629; anti-hsa-miR-106b, cat.n: AM10067; anti-hsa-miR-128, cat.n: AM11746; anti-hsa-miR-155, cat.n: AM12601.

Anti-miR transfections were performed using INTERFERin, as recommended by the manufacturer’s protocol. BEAS-2B cells were seeded at 0.75 × 105 cells/well in 24-well plates. Twenty four hours later, the culture medium was replaced with 500 μL/well of growth medium. For each well to be transfected, 1.2 μL of 50 μmol/L anti-miR were diluted in 100 μL of plain RPMI and mixed by pipetting. Immediately after, 4 μL of INTERFERin were added and mixed by pipetting. After 20 min incubation at room temperature, 100 μL/well were used, giving a final anti-miR concentration of 100 nmol/L. The following day, cells were infected with HRV-1B.

***Lentivirally transduced BEAS-2B cell lines***

The lentivirally transduced BEAS-2B cell lines were generated as previously described[45]. The genomic region encompassing miR-155 was amplified using the following primers, forward: AAGCTTTATGCCTCATCCTCTGAGTGC; reverse: CTCGAGACGAAGGTTGAACATCCCAGTGACC. The insert was cloned into pSUPER plasmid between the sites HindIII and XhoI, excised with EcoRI and MluI and hence subcloned in pLVTHM, generating the construct pLVTHM\_BIC.

HEK293T cells were co-transfected with 5 μg of pLVTHM\_BIC (containing miR-155) or pLVTHM (used as negative control) 3.75 μg of pPAX2 and 1.5 μg of pMD2G using Superfect (Qiagen) according to the manufacturer’s protocol. Supernatants were used to transduce BEAS-2B cells. Four days after transduction, selection of positively transduced cells (GFP+) was achieved by cell sorting, performed on a BD FACSAria III cell sorter.

***RT-qPCR analysis***

Total cellular RNA was extracted using TRI-Reagent (Ambion) according to the manufacturer’s instructions. RNA samples were quantified using the spectrophotometer Nanodrop 1000 (Thermo Scientific). Reverse transcription (RT) reactions were performed using the same amount of RNA for all samples, using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems part number: 4368813) with random hexamers as primers. MicroRNA RT-qPCR was performed using Taqman microRNA assay kits from applied biosystems (part number: 4427975) that contain a specific RT primer and Taqman qPCR primers and probe necessary to quantify expression of a specific microRNA. In both cases, the cDNA obtained was used to perform qPCR using TaqMan® Universal PCR Master Mix, No AmpErase® UNG (Applied Biosystems part number: 4364341) on a 7900HT Real-Time PCR machine (Applied Biosystems) with the standard Taqman thermal cycling conditions for assays using “Taqman probes” (95° C for 10 min; 95 °C for 15 sec; 60 °C for 1 min - data collection) or modified as follows for assays using “Perfect probe” (95 °C for 10 min; 95 °C for 15 s; 50 °C for 30 s - data collection; 72 °C for 15 s). Fold differences in gene expression were calculated using the comparative Ct method for relative quantification[46]. Unless otherwise stated, gene expression was calculated using GAPDH as reference gene, and the average delta Ct value of the negative control as calibrator. Gene expression assays from Applied Biosystems (part n: 4331182): AGO2 (EIF2C2 - Assay ID: Hs01085579\_m1); COL1A1 (Assay ID: Hs00164004\_m1); DICER1 (Assay ID: Hs00229023\_m1); GAPDH (part n: 4352934); SMAD2 (Assay ID: Hs00183425\_m1). Gene expression assays from PrimerDesign Ltd (Southampton, UK): HRV-1B (Taqman probe); and IFNB1 (Perfect probe); IL13RA1 (Taqman probe); PU.1 (Taqman probe). MicroRNA expression assays (part n: 4427975): hsa-miR-18a (Assay ID: 002422); hsa-miR-19b (Assay ID: 000396); hsa-miR-106b (Assay ID: 000442); hsa-miR-128 (Assay ID: 002216); hsa-miR-155 (Assay ID: 002623).

***Co-immunoprecipiation protocol***

The antibodies used were: anti-AGO2, clone 11A9 (rat IgG2a) available from Ascenion GmbH, Munich, Germany[47]; normal rat IgG (cat.n: sc-2026, Santa Cruz biotechnology, inc). Protein G-coated Sepharose beads (Amersham) were prepared for IP reactions as follows. Beads were collected by centrifugation in a bench top centrifuge, at 3000 rpm (= 800 × g) for 1 min at 4 °C. Beads were washed 3 times with ice-cold lysis buffer (PBS 1X, NP-40 0.5%, EDTA pH8 2 mmol/L, Glycerol 20%). Beads were then blocked in ice-cold lysis buffer with a final concentration of 1 mg/mL of BSA and 1 mg/mL of sonicated salmon sperm DNA (sspDNA) rotating end over end, for at least 1 h at 4 °C. After this incubation, beads were collected by centrifugation and washed three times as above and resuspended in an equal volume of ice-cold lysis buffer.

THP-1 cells (human monocyte cell line, used as an additional control) were collected by centrifugation at 300 × g for 5 min at 4 °C. BEAS-2B cells were first trypsinised to detach them from the plastic. Trypsin was inhibited by adding growth medium (containing 10% FBS) and cells were then collected by centrifugation as above. In both cases, cells were then washed twice in sterile ice-cold PBS (GIBCO) and finally the cell pellet was resuspended in 50 μL/106 cells of ice-cold complete lysis buffer (composed as specified above and containing in addition 100 U/mL RNAse inhibitor – Applied Biosystems; 1X complete cocktail protease inhibitor – Roche; DTT 0.5 mmol/L, all added just before use) incubated on ice for 10 minutes. Cell lysates were kept on ice during the entire procedure. They were cleared of the residual cell debris by centrifugation, at top speed in a bench top microcentrifuge, at 4 °C for 15 min. Pellets were discarded while supernatants were collected and diluted ten times, so that 1 mL of lysate would correspond to 2 × 106 cells. One mL aliquots were dispensed in pre-chilled eppendorfs, while 10 μL were placed into 0.5 mL of TRI-Reagent and constitute the input sample. The same amount of anti-AGO2 specific antibody or the corresponding IgG negative control isotype antibody was then added to each 1mL-aliquot of cell lysate at this stage and finally, the samples were left rotating end over end at 4 °C overnight. 50 μL of protein G-coated sepharose beads, prepared as described above, were added to each co-IP reaction, and incubated rotating end over end at 4 °C for 2 h. Beads were then collected by centrifugation and then washed five times as already described, using 1mL of ice-cold washing buffer. The latter was different for THP-1 (PBS 1X, NaCl 160 mM, NP-40 0.05%, Glycerol 10%) or BEAS-2B cells (PBS 1X, NaCl 860 mM, NP-40 0.05%, Glycerol 10%). Beads were then washed once more with ice-cold PBS (1x) and resuspended in 100 μL of RNAse-free water. 2.5 μL of proteinase K (20 mg/mL) was added to each tube. Beads were incubated for 15 min at 37 °C in a rotomixer at 1000rpm. Finally, 500 μL of TRI-Reagent (Ambion) were added to each tube. Beads were then vortexed briefly and incubated at room temperature for about 10 min. Eppendorfs were then spun at top speed in a bench-top centrifuge for 1 min. Supernatants were transferred into new eppendorfs while the collected beads were discarded. RNA isolation was then performed as usual. The isolated RNA, was then either used straightaway for RT-qPCR reactions, or stored at -80 °C for later use.

***AGO2 co-IP calculations***

Relative RNA levels were calculated using the following formula: 2-[Ct(IP) – Ct(Input)]/2-[Ct(GAPDH IgG) – Ct(Input)]. Inclusion of the Ct values from the input normalises for mRNA abundance in the cell lysate.

***Bioinformatics analysis***

The genomic sequences of different HRVs were obtained from the National Center for Biotechnology Information (NCBI) website. HRV-1B version number D00239.1; HRV-16 version number L24917.1; HRV-14 version number K02121.1; HRV-27 version number FJ445186.1.

The microRNA sequences used with Targetscan[48] were obtained from[49]. The microRNA sequences used with miRanda[50] and PITA[51] were obtained from miRBase 21[52]. Mature microRNA sequences for miR-18a, -19b, -106b, -128, -155, were identical across the two datasets and are reported in Table 1. MicroRNA target site predictions on viral genomes were obtained by running the appropriate program, locally on a Linux Ubuntu 10.04 LTS system. TargetScan software version 6, miRanda 3.3a and PITA were run with default parameters.

Results were then sorted by context+ score for Targetscan, Energy for miRanda and ddG for PITA. No cut-off value is recommended for Targetscan; Energy threshold of -7 (for miRanda) and ddG threshold of -10 (for PITA[53]) are recommended, besides the default parameters.

In Targetscan, the context+ score is calculated based on the seed class (6-mer, 7-mer-1a, 7-mer-m8 or 8-mer), the extent of miR 3’-binding, the miR:target stability, the AU composition of the target site, its distance from the closest end of the target RNA, and the number of sites on the same target RNA.

MiRanda first identifies regions of complementarity between miR and target RNA and afterwards calculates the free energy of the RNA duplex.

In PITA, after the identification of possible RNA duplexes, the algorithm calculates the net free energy (ddG). The latter is the difference between the stability of the miR:target (energy gained, dGduplex) minus the energy necessary to unfold the region surrounding the target site (dGopen) which is necessary for microRNA binding.

The schematics showing the bioinformatics predictions were generated using BioPerl[54].

***Statistical analysis***

Statistical significance was calculated using the tools integrated in the software GraphPad Prism v.6. Unless otherwise stated, the unpaired t-test was used for pairwise comparisons. If multiple conditions were compared altogether, one-way ANOVA with Bonferroni post-test correction was used.

**RESULTS**

***DICER knock-down favours HRV-1B replication***

In order to test if microRNAs have a role during HRV infection of bronchial epithelial cells, we disrupted the biogenesis of microRNAs by knocking-down DICER in BEAS-2B cells. The latter is a virally immortalized cell line derived from healthy human bronchial epithelial cells[55] that has often been employed as a convenient model for HRV infection of this cell type, *e.g.*[56]. To establish if DICER knock-down would compromise substantially the expression of mature microRNAs, we performed several rounds of transfection with either siRNA against DICER, or negative control siRNA. Total cellular RNA was extracted 48 h after each transfection (Figure 1A) and the siRNA efficacy was verified measuring DICER mRNA by RT-qPCR. In addition, we measured the expression of 4 miRs (miR-155, -140, -92, 30a-5p) to detect changes in the production of cellular microRNAs (Figure 1B). On the one hand, we found that DICER mRNA was significantly and consistently reduced by the anti-DICER siRNA since the first round of transfection. On the other hand, 48 h after the first transfection, the levels of mature microRNAs were only marginally affected compared to negative control. In fact, the microRNAs appeared to be reduced by less than 50% and such a difference was not statistically significant. After the second and third round of transfection instead, all four microRNAs were significantly reduced, with residual levels scoring below 50% of the respective negative controls. Therefore, we infected BEAS-2B cells with three different doses of HRV-1B, after three rounds of siRNA transfection (Figure 2). For each dose of virus used, DICER knock-down increased the intracellular levels of viral RNA, as measured 8 h post-infection (HPI). This experiment was repeated three more times using only the intermediate dose of virus (MOI = 0.01) confirming the previous results: cells lacking microRNAs (Figure 3A and B) had about 40% more viral RNA than negative control, both at 8 and 24 h post-infection (Figure 3C). Crucially, the levels of IFN-beta mRNA were not different between cells transfected with either anti-DICER or negative control siRNA (Figure 3D). This suggested that DICER knock-down did not alter the expression of IFN-beta neither before nor during viral infection. Therefore, higher levels of viral RNA were not due to altered IFN-beta induction, suggesting that the disruption of microRNA maturation affected viral replication through a mechanism independent from the IFN-beta pathway. Considering that there was no difference in the level of viral RNA that entered the cells (0 h post-infection) but differences were detected only at 8 and 24 h post-infection, the mechanism responsible for the higher accumulation of intracellular viral RNA was likely to involve intracellular events of viral replication. Given these considerations, we speculated that one possibility was that mature microRNAs interacted directly with the viral genome. Such interaction would hamper viral replication even if only mildly, as the results from our DICER knock-down experiment suggest.

***AGO2 protein interacts with HRV-1B RNA***

In order to test if microRNAs interacted directly with the RNA of HRV-1B, we performed RNA immunoprecipitations using an antibody specific for AGO2 (AGO2 co-IP thereafter). With this technique (Figure 4A), it is possible to identify the mRNA molecules that are bound by AGO2 protein and therefore, are targeted by microRNAs[47]. Although human cells express 4 Argonaute proteins (AGO1-4) several reports showed that they associate to largely overlapping pools of microRNAs and target mRNAs. Moreover, AGO2 co-IP has been shown to correctly identify direct targets of both endogenous and exogenously added microRNAs, *e.g.*[57–61]. In addition, we validated the choice of AGO2 in our protocol by showing that microRNAs were strongly co-purified and that mRNAs, already known to be microRNA targets, could be readily detected in the immunoprecipitated fraction (Figure 5). BEAS-2B cells were infected with HRV-1B, and AGO2 co-IP was performed on cells harvested 6 h post-infection (Figure 4B). Under these conditions, AGO2 was as strongly associated with HRV-1B RNA as it was with SMAD2 mRNA. The latter constitutes a positive control, as it has already been shown to be a target of miR-155[62]. In contrast, GAPDH was not significantly co-precipitated with AGO2, as compared to when an irrelevant antibody was used. The interaction of AGO2 with the genomic RNA of HRV-1B suggested that the latter may be bound by microRNAs during infection of bronchial epithelial cells.

***Antagonists of miR-155 or miR-128 enhance HRV-1B replication***

To identify specific microRNAs that could directly target HRV-1B, we performed a bioinformatics analysis. We ran Targetscan[5] using a list of microRNAs that we found to be expressed in human primary bronchial epithelial cells (PBECs) as measured by Taqman low density microRNA arrays (Table 2). A number of those microRNAs were predicted to target HRV-1B with varying degrees of efficiency, as summarized by the “context+ score” where the lower the value the better. Among these, we focused on microRNAs that were also shown to be under-expressed in the asthmatic bronchial epithelium[63]. We selected one microRNA (miR-18a) predicted to be very efficient at targeting the virus, two microRNAs with average scores (miR-155 and miR-128) and two microRNAs predicted to be less likely to target the virus (miR-106b and miR-19b) (Table 3). In addition, the five microRNAs had putative sites also on other Rhinoviruses such as HRV-16, -14, -27. Interestingly, of the five microRNAs, miR-155 was predicted to target all the tested genomes in a very similar region at their 3’ end (Table 3 and Figure 6).

In order to test experimentally the *in-silico* predictions, we transfected BEAS-2B cells with microRNA antagonists (anti-miRs). To test the efficiency of anti-miR transfection, we measured the expression of miR-18a, -106b, -128 and -155 by RT-qPCR, 24 h post-transfection (Figure 7) confirming reduction (from 70% to 90%) of the measured microRNAs. Twenty four hours after anti-miR transfection, BEAS-2B cells were infected with HRV-1B. Cells were collected 8 h post-infection and viral RNA was quantified by RT-qPCR (Figure 8). The results showed that, as expected given their positive “context + scores”, miR-106b and miR-19b did not alter viral replication. The microRNA predicted to be the best match for HRV-1B, miR-18a, did not affect viral replication either. However, when miR-155 or miR-128 was silenced, we observed an increase in viral RNA of approximately 50% compared to a negative control anti-miR. Notably, the different constructs transfected did not alter the levels of GAPDH mRNA across all the samples of infected cells (Figure 9B). As an additional control we also noted that the total cellular RNA did not change among the samples transfected with specific anti-miRs (Figure 9A). In addition, the same analysis on independently transfected cells that were not subsequently infected with HRV-1B (Figure 9C and D) confirmed that these parameters were not affected by any of the anti-miRs used. These observations suggest that the measured increase of intracellular viral RNA was not influenced by the normalisation method adopted, and that in our experiments cell viability was not significantly altered by the different anti-miRs transfected.

Finally, we generated two lentivirally transduced BEAS-2B cell lines, in order to study the effect of miR-155 over-expression on the replication of HRV-1B (Figure 10). These experiments showed that from 40% to 50% less viral RNA accumulated in cells that over-expressed miR-155, compared to the relative negative control, thus reinforcing the results obtained for this microRNA in the anti-miR experiments.

**DISCUSSION**

Innate immunity plays a vital role in the antiviral response of human cells. In particular, the importance of the IFN system in antiviral immunity has been long recognized and studied[64]. Early, innate immune responses are particularly well suited for protection from viruses that result in acute infections, such as Rhinoviruses. Although it is still under debate whether virus-induced RNA interference (RNAi) is an antiviral mechanism actually conserved in human cells[65,66] it has become clear that microRNAs play an important role in human innate antiviral immunity.

We hypothesized that microRNAs inhibit the replication of human Rhinoviruses. This would be of interest in the fields of asthma and COPD, since Rhinoviruses constitute major exacerbation triggers of these conditions. In particular, it has been shown that Rhinoviruses replicate more in PBECs from asthmatics than in cells from healthy subjects and that the former express less INF-beta and IFN–gamma during infection[44,67]. Recently, it has been reported that the bronchial epithelium of asthmatics present a dysregulated microRNA profile[63] with prevalence of under-expressed microRNAs. Therefore, if microRNAs that are under-expressed in asthmatic PBECs were able to hold back Rhinovirus replication, it can be speculated that also their deficiency may contribute to the weaker antiviral immunity of asthmatic cells.

MicroRNA maturation involves the activity of two endonucleases that progressively shorten the initial transcript. DROSHA cleaves the primary microRNA (pri-miR) in the nucleus, while DICER is responsible for trimming the precursor microRNA (pre-miR) in the cytoplasm, and finally the mature microRNA assembles with AGO proteins in order to be functional[3,4]. Hence, impairing the activity of either DROSHA or DICER has been shown to lead to a reduction of mature microRNAs[68,69]. In order to test whether microRNAs affect the replication of Human Rhinovirus, we opted to target DICER in bronchial epithelial cells. A very specific protocol had to be followed to generate the desired knock down of microRNAs; transfecting BEAS-2B cells with anti-DICER siRNA for three consecutive times showed that microRNAs were reduced to about 40%-30% only after the second round of transfection (Figure 1) equivalent to five days of DICER silencing.

Our results are in agreement with other published work where, 48 h after transfection of anti-DICER siRNA, only a subset of microRNAs was affected, and in general their reduction was very rarely above 50%[68,70–72]. Schmitter *et al*[69] showed that an anti-DICER shRNA had to be expressed for at least 3 to 7 d in HEK cells, in order to effectively abolish microRNA repression of a luciferase construct. In addition, Gantier *et al*[73] specifically studied microRNA stability, showing that different miRs have different turnover rates, and estimated that the average half-life in HEK cells is about 5 d.

DICER knock-down, and the subsequent reduction of microRNAs, allowed an increase of viral RNA following infection with HRV-1B (Figure 3) suggesting that the microRNA machinery affected the intracellular stages of Rhinovirus replication. In addition, considering that AGO proteins are responsible for the activity of microRNAs, our AGO2 co-IP results suggest that microRNAs bound the viral RNA during infection of bronchial epithelial cells (Figure 4). This encouraged us to use bioinformatics in order to identify possible antiviral microRNA candidates. From the candidates identified by Targetscan, we selected five microRNAs known to be deficient in asthmatic PBECs: miR-18a, -19b, -106b, -128 and -155 ([63] and our data, not shown). Using anti-miRs, we confirmed that, out of those microRNAs, miR-128 and miR-155 had antiviral activity against HRV-1B in BEAS-2B cells (Figure 8): inhibition of miR-128 or miR-155 lead to a modest but significant increase of viral RNA, which was roughly similar to what obtained by the prolonged DICER silencing. Conversely, miR-155 overexpression inhibited viral replication (Figure 10).

MicroRNA-128 has been shown to play an important role in the control of apoptosis in glioblastoma[74–76]. MiR-128 has also been shown to regulate EGFR expression in non-small-cell lung cancer (NSCLC) cell lines[77] and to be down-regulated in the airway epithelium of smokers[78]. It would certainly be of interest to investigate whether the lack of miR-128 in asthmatic PBECs contributes to their higher EGFR expression[79] or if this microRNA affects the virally induced apoptosis in bronchial epithelial cells[44]. However, considering the short time post-infection adopted (8 h), it seems unlikely that in our experiments the inhibition of miR-128 increased viral replication by affecting the induction of apoptosis.

MicroRNA-155 plays an important role in different processes[80] from physiological ones such as haematopoiesis, cellular differentiation and immune responses, to malignancies[13,81–85]. Importantly, miR-155 has been shown to be up-regulated by a series of microbial components such as lipopolysaccharide (LPS). Although the functions of miR-155 in non-hematopoietic cells have been much less studied, the antiviral activity we postulate for miR-155 in bronchial epithelial cells would fit with the large involvement of this microRNA in immunity.

It was surprising that the inhibition of miR-18a did not affect HRV-1B replication, despite the promising context+ score calculated by Targetscan. Therefore, we used two additional microRNA predictive programs on HRV-1B: miRanda and PITA (see Figure 11 and Tables 4 and 5). Despite large overlap between the sites identified by Targetscan and miRanda, the latter did not find a miR-18a target on HRV-1B. PITA identified favourable sites only for miR-155, -128 and -106b, in order of predicted efficiency. In combination with our experimental results (only miR-128 and -155 affected viral replication) this analysis highlights the importance to adopt multiple prediction algorithms. Moreover, the results from PITA suggest that the presence of secondary structures in the viral genome may prevent miR-18a from interacting with its target site. As a matter of fact, target site accessibility has been shown to be an important factor in determining microRNA efficacy[51]. Of the three algorithms, PITA is the only one to take into account this feature of microRNA biology (see materials and methods for more details). Notably, PITA could identify all the sites also predicted by Targetscan, but estimated their accessibility too low for the microRNA to have an effect on HRV-1B (Table 6).

The Rhinovirus genomic RNA is directly translated into a single polyprotein which further matures into separate proteins. Therefore, it is a single transcriptional unit i.e. it is comparable to a single cellular mRNA. However, while miRs are often found to target the 3’UTR of cellular mRNAs, the putative miR sites for HRV-1B fall within the coding region (Figure 11). This is in agreement with what already shown for HCV[23] and Influenza virus[28] and represents a striking difference between microRNA targets on cellular mRNAs and those on viral RNA.

Further investigation is needed to understand the mechanistic details of what shown by our experiments. Our results cannot exclude the possibility that the observed effects were due to an indirect mechanism. It could be argued that the microRNA inhibitors could have affected the IFN-related antiviral machinery. For instance, miR-155 has been shown to target SOCS1, an inhibitor of type I IFN signalling[86]. So, it can be assumed that the inhibition of miR-155 would favour viral replication by increasing SOCS1. However, also miR-19b has been shown to target SOCS1[87] but, in our experiments, the inhibition of this microRNA did not have any effect on viral replication.

Despite these limitations, our data altogether suggest that HRV-1B may be directly targeted by microRNAs. In fact (1) prolonged DICER knock-down did not affect the basal levels of IFN-beta mRNA or its induction by infection; (2) AGO2 protein interacted with HRV-1B RNA during viral replication (6 h post-infection); (3) miR-155 and miR-128 have putative target sites on HRV-1B, as predicted by three different bioinformatics tools; and (4) inhibition of either miR led to a modest but significant increase of intracellular viral RNA, while over-expression of miR-155 had the opposite effect.

In conclusion, our study suggests that cellular microRNAs play a role in the innate immune response against Rhinoviruses. We also showed that two microRNAs that are under-expressed in the asthmatic epithelium, can affect HRV-1B replication. Therefore, our work encourages speculating that the asthmatic microRNA deficiency recently uncovered[63,88] may contribute to the higher replication of Rhinoviruses in asthmatic PBECs.

**COMMENTS**

***Background***

Human Rhinovirus (HRV) is one of the major causes of asthma and chronic obstructive pulmonary disease (COPD) exacerbations, which can be life threatening and represent an unmet clinical need. MicroRNAs, non-coding RNA molecules that regulate gene expression, also participate in innate antiviral immunity.

***Research frontiers***

Bronchial epithelial cells from asthmatic patients have a defective innate immune response to human rhinovirus (HRV) infection, notably by producing lower levels of IFNs, compared to cells from healthy subjects. However, the role of microRNAs in such insufficient immune response has not been investigated, despite the recent finding that microRNA expression is dysregulated in asthmatic cells.

***Innovations and breakthroughs***

Several reports have highlighted the importance of microRNAs as part of the innate antiviral immunity. Often, microRNAs have been shown to inhibit viral replication by directly targeting viral RNA. While it has been demonstrated that miR-23b could limit HRV replication by an indirect mechanism, this is the first report showing evidence of direct interaction between the microRNA machinery and HRV RNA.

***Applications***

By uncovering a role for microRNAs in the antiviral response of bronchial epithelial cells to HRV, this study may inspire future strategies for therapeutic intervention in the management of HRV-induced exacerbations of asthma and COPD.

***Terminology***

MicroRNAs are short RNA molecules that generally inhibit gene expression by binding to partially complementary sequences in the 3’ Un-Translated Region (UTR) of cellular mRNAs. Such inhibition can involve both increased mRNA degradation and inhibition of translation.

***Peer review***

In the manuscript, some interesting results have been observed that both miR-128 and miR-155 target HRV-1B. Over-expression of miR-155 inhibits HRV-1B RNA accumulated in BEAS-2B cell line.

**REFERENCES**

1 **Bartel DP**. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004; **116**: 281-297 [PMID: 14744438 DOI: 10.1016/S0092-8674(04)00045-5]

2 **Meister G**, Landthaler M, Patkaniowska A, Dorsett Y, Teng G, Tuschl T. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. *Mol Cell* 2004; **15**: 185-197 [PMID: 15260970 DOI: 10.1016/j.molcel.2004.07.007]

3 **Peters L**, Meister G. Argonaute proteins: mediators of RNA silencing. *Mol Cell* 2007; **26**: 611-623 [PMID: 17560368 DOI: 10.1016/j.molcel.2007.05.001]

4 **Filipowicz W**, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? *Nat Rev Genet* 2008; **9**: 102-114 [PMID: 18197166 DOI: 10.1038/nrg2290]

5 **Lewis BP**, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 2005; **120**: 15-20 [PMID: 15652477 DOI: 10.1016/j.cell.2004.12.035]

6 **Garzon R**, Calin GA, Croce CM. MicroRNAs in Cancer. *Annu Rev Med* 2009; **60**: 167-179 [PMID: 19630570 DOI: 10.1146/annurev.med.59.053006.104707]

7 **Bernstein E**, Kim SY, Carmell MA, Murchison EP, Alcorn H, Li MZ, Mills AA, Elledge SJ, Anderson KV, Hannon GJ. Dicer is essential for mouse development. *Nat Genet* 2003; **35**: 215-217 [PMID: 14528307 DOI: 10.1038/ng1253]

8 **Harris KS**, Zhang Z, McManus MT, Harfe BD, Sun X. Dicer function is essential for lung epithelium morphogenesis. *Proc Natl Acad Sci U S A* 2006; **103**: 2208-2213 [PMID: 16452165 DOI: 10.1073/pnas.0510839103]

9 **Williams AE**, Moschos SA, Perry MM, Barnes PJ, Lindsay MA. Maternally imprinted microRNAs are differentially expressed during mouse and human lung development. *Dev Dyn* 2007; **236**: 572-580 [PMID: 17191223 DOI: 10.1002/dvdy.21047]

10 **Tomankova T**, Petrek M, Kriegova E. Involvement of microRNAs in physiological and pathological processes in the lung. *Respir Res* 2010; **11**: 159 [PMID: 21092244 DOI: 10.1186/1465-9921-11-159]

11 **Martinez-Anton A**, Sokolowska M, Kern S, Davis AS, Alsaaty S, Taubenberger JK, Sun J, Cai R, Danner RL, Eberlein M, Logun C, Shelhamer JH. Changes in microRNA and mRNA expression with differentiation of human bronchial epithelial cells. *Am J Respir Cell Mol Biol* 2013; **49**: 384-395 [PMID: 23590309 DOI: 10.1165/rcmb.2012-0368OC]

12 **Rodriguez A**, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van Dongen S, Grocock RJ, Das PP, Miska EA, Vetrie D, Okkenhaug K, Enright AJ, Dougan G, Turner M, Bradley A. Requirement of bic/microRNA-155 for normal immune function. *Science* 2007; **316**: 608-611 [PMID: 17463290 DOI: 10.1126/science.1139253]

13 **O'Connell RM**, Taganov KD, Boldin MP, Cheng G, Baltimore D. MicroRNA-155 is induced during the macrophage inflammatory response. *Proc Natl Acad Sci U S A* 2007; **104**: 1604-1609 [PMID: 17242365 DOI: 10.1073/pnas.0610731104]

14 **Tili E**, Michaille JJ, Cimino A, Costinean S, Dumitru CD, Adair B, Fabbri M, Alder H, Liu CG, Calin GA, Croce CM. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. *J Immunol* 2007; **179**: 5082-5089 [PMID: 17911593 DOI: 10.4049/jimmunol.179.8.5082]

15 **Taganov KD**, Boldin MP, Chang KJ, Baltimore D. NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. *Proc Natl Acad Sci U S A* 2006; **103**: 12481-12486 [PMID: 16885212 DOI: 10.1073/pnas.0605298103]

16 **Hou J**, Wang P, Lin L, Liu X, Ma F, An H, Wang Z, Cao X. MicroRNA-146a feedback inhibits RIG-I-dependent Type I IFN production in macrophages by targeting TRAF6, IRAK1, and IRAK2. *J Immunol* 2009; **183**: 2150-2158 [PMID: 19596990 DOI: 10.4049/jimmunol.0900707]

17 **Buggele WA**, Johnson KE, Horvath CM. Influenza A virus infection of human respiratory cells induces primary microRNA expression. *J Biol Chem* 2012; **287**: 31027-31040 [PMID: 22822053 DOI: 10.1074/jbc.M112.387670]

18 **Thornburg NJ**, Hayward SL, Crowe JE. Respiratory syncytial virus regulates human microRNAs by using mechanisms involving beta interferon and NF-κB. *MBio* 2012; **3**: [PMID: 23249809 DOI: 10.1128/mBio.00220-12]

19 **Bakre A**, Mitchell P, Coleman JK, Jones LP, Saavedra G, Teng M, Tompkins SM, Tripp RA. Respiratory syncytial virus modifies microRNAs regulating host genes that affect virus replication. *J Gen Virol* 2012; **93**: 2346-2356 [PMID: 22894925 DOI: 10.1099/vir.0.044255-0]

20 **Othumpangat S**, Walton C, Piedimonte G. MicroRNA-221 modulates RSV replication in human bronchial epithelium by targeting NGF expression. *PLoS One* 2012; **7**: e30030 [PMID: 22272270 DOI: 10.1371/journal.pone.0030030]

21 **Müller S**, Imler JL. Dicing with viruses: microRNAs as antiviral factors. *Immunity* 2007; **27**: 1-3 [PMID: 17663977 DOI: 10.1016/j.immuni.2007.07.003]

22 **Jopling CL**, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. *Science* 2005; **309**: 1577-1581 [PMID: 16141076 DOI: 10.1126/science.1113329]

23 **Pedersen IM**, Cheng G, Wieland S, Volinia S, Croce CM, Chisari FV, David M. Interferon modulation of cellular microRNAs as an antiviral mechanism. *Nature* 2007; **449**: 919-922 [PMID: 17943132 DOI: 10.1038/nature06205]

24 **Ouda R**, Onomoto K, Takahasi K, Edwards MR, Kato H, Yoneyama M, Fujita T. Retinoic acid-inducible gene I-inducible miR-23b inhibits infections by minor group rhinoviruses through down-regulation of the very low density lipoprotein receptor. *J Biol Chem* 2011; **286**: 26210-26219 [PMID: 21642441 DOI: 10.1074/jbc.M111.229856]

25 **Otsuka M**, Jing Q, Georgel P, New L, Chen J, Mols J, Kang YJ, Jiang Z, Du X, Cook R, Das SC, Pattnaik AK, Beutler B, Han J. Hypersusceptibility to vesicular stomatitis virus infection in Dicer1-deficient mice is due to impaired miR24 and miR93 expression. *Immunity* 2007; **27**: 123-134 [PMID: 17613256 DOI: 10.1016/j.immuni.2007.05.014]

26 **Matskevich AA**, Moelling K. Dicer is involved in protection against influenza A virus infection. *J Gen Virol* 2007; **88**: 2627-2635 [PMID: 17872512 DOI: 10.1099/vir.0.83103-0]

27 **Ma YJ**, Yang J, Fan XL, Zhao HB, Hu W, Li ZP, Yu GC, Ding XR, Wang JZ, Bo XC, Zheng XF, Zhou Z, Wang SQ. Cellular microRNA let-7c inhibits M1 protein expression of the H1N1 influenza A virus in infected human lung epithelial cells. *J Cell Mol Med* 2012; **16**: 2539-2546 [PMID: 22452878 DOI: 10.1111/j.1582-4934.2012.01572.x]

28 **Song L**, Liu H, Gao S, Jiang W, Huang W. Cellular microRNAs inhibit replication of the H1N1 influenza A virus in infected cells. *J Virol* 2010; **84**: 8849-8860 [PMID: 20554777 DOI: 10.1128/JVI.00456-10]

29 **Triboulet R**, Mari B, Lin YL, Chable-Bessia C, Bennasser Y, Lebrigand K, Cardinaud B, Maurin T, Barbry P, Baillat V, Reynes J, Corbeau P, Jeang KT, Benkirane M. Suppression of microRNA-silencing pathway by HIV-1 during virus replication. *Science* 2007; **315**: 1579-1582 [PMID: 17322031 DOI: 10.1126/science.1136319]

30 **Lecellier CH**, Dunoyer P, Arar K, Lehmann-Che J, Eyquem S, Himber C, Saïb A, Voinnet O. A cellular microRNA mediates antiviral defense in human cells. *Science* 2005; **308**: 557-560 [PMID: 15845854 DOI: 10.1126/science.1108784]

31 **Johnston SL**, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, Symington P, O'Toole S, Myint SH, Tyrrell DA. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. *BMJ* 1995; **310**: 1225-1229 [PMID: 7767192 DOI: 10.1136/bmj.310.6989.1225]

32 **Johnston NW**, Johnston SL, Duncan JM, Greene JM, Kebadze T, Keith PK, Roy M, Waserman S, Sears MR. The September epidemic of asthma exacerbations in children: a search for etiology. *J Allergy Clin Immunol* 2005; **115**: 132-138 [PMID: 15637559 DOI: 10.1016/j.jaci.2004.09.025]

33 **Seemungal TA**, Harper-Owen R, Bhowmik A, Jeffries DJ, Wedzicha JA. Detection of rhinovirus in induced sputum at exacerbation of chronic obstructive pulmonary disease. *Eur Respir J* 2000; **16**: 677-683 [PMID: 11106212 DOI: 10.1034/j.1399-3003.2000.16d19.x]

34 **Gern JE**, Galagan DM, Jarjour NN, Dick EC, Busse WW. Detection of rhinovirus RNA in lower airway cells during experimentally induced infection. *Am J Respir Crit Care Med* 1997; **155**: 1159-1161 [PMID: 9117003 DOI: 10.1164/ajrccm.155.3.9117003]

35 **Friedlander SL**, Busse WW. The role of rhinovirus in asthma exacerbations. *J Allergy Clin Immunol* 2005; **116**: 267-273 [PMID: 16083778 DOI: 10.1016/j.jaci.2005.06.003]

36 **Hayden FG**. Rhinovirus and the lower respiratory tract. *Rev Med Virol* 2004; **14**: 17-31 [PMID: 14716689 DOI: 10.1002/rmv.406]

37 **Mosser AG**, Brockman-Schneider R, Amineva S, Burchell L, Sedgwick JB, Busse WW, Gern JE. Similar frequency of rhinovirus-infectible cells in upper and lower airway epithelium. *J Infect Dis* 2002; **185**: 734-743 [PMID: 11920291 DOI: 10.1086/339339]

38 **Greve JM**, Davis G, Meyer AM, Forte CP, Yost SC, Marlor CW, Kamarck ME, McClelland A. The major human rhinovirus receptor is ICAM-1. *Cell* 1989; **56**: 839-847 [PMID: 2538243 DOI: 10.1016/0092-8674(89)90688-0]

39 **Hofer F**, Gruenberger M, Kowalski H, Machat H, Huettinger M, Kuechler E, Blaas D. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. *Proc Natl Acad Sci U S A* 1994; **91**: 1839-1842 [PMID: 8127891 DOI: 10.1073/pnas.91.5.1839]

40 **Wang Q**, Nagarkar DR, Bowman ER, Schneider D, Gosangi B, Lei J, Zhao Y, McHenry CL, Burgens RV, Miller DJ, Sajjan U, Hershenson MB. Role of double-stranded RNA pattern recognition receptors in rhinovirus-induced airway epithelial cell responses. *J Immunol* 2009; **183**: 6989-6997 [PMID: 19890046 DOI: 10.4049/jimmunol.0901386]

41 **Slater L**, Bartlett NW, Haas JJ, Zhu J, Message SD, Walton RP, Sykes A, Dahdaleh S, Clarke DL, Belvisi MG, Kon OM, Fujita T, Jeffery PK, Johnston SL, Edwards MR. Co-ordinated role of TLR3, RIG-I and MDA5 in the innate response to rhinovirus in bronchial epithelium. *PLoS Pathog* 2010; **6**: e1001178 [PMID: 21079690 DOI: 10.1371/journal.ppat.1001178]

42 **Watanabe Y**, Kishi A, Yachie N, Kanai A, Tomita M. Computational analysis of microRNA-mediated antiviral defense in humans. *FEBS Lett* 2007; **581**: 4603-4610 [PMID: 17825824 DOI: 10.1016/j.febslet.2007.08.049]

43 **Phipps KM**, Martinez A, Lu J, Heinz BA, Zhao G. Small interfering RNA molecules as potential anti-human rhinovirus agents: in vitro potency, specificity, and mechanism. *Antiviral Res* 2004; **61**: 49-55 [PMID: 14670593 DOI: 10.1016/j.antiviral.2003.08.005]

44 **Wark PA**, Johnston SL, Bucchieri F, Powell R, Puddicombe S, Laza-Stanca V, Holgate ST, Davies DE. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. *J Exp Med* 2005; **201**: 937-947 [PMID: 15781584 DOI: 10.1084/jem.20041901]

45 **Martinez-Nunez RT**, Louafi F, Friedmann PS, Sanchez-Elsner T. MicroRNA-155 modulates the pathogen binding ability of dendritic cells (DCs) by down-regulation of DC-specific intercellular adhesion molecule-3 grabbing non-integrin (DC-SIGN). *J Biol Chem* 2009; **284**: 16334-16342 [PMID: 19386588 DOI: 10.1074/jbc.M109.011601]

46 **Livak KJ**, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. *Methods* 2001; **25**: 402-408 [PMID: 11846609 DOI: 10.1006/meth.2001.1262]

47 **Rüdel S**, Flatley A, Weinmann L, Kremmer E, Meister G. A multifunctional human Argonaute2-specific monoclonal antibody. *RNA* 2008; **14**: 1244-1253 [PMID: 18430891 DOI: 10.1261/rna.973808]

48 **Garcia DM**, Baek D, Shin C, Bell GW, Grimson A, Bartel DP. Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. *Nat Struct Mol Biol* 2011; **18**: 1139-1146 [PMID: 21909094 DOI: 10.1038/nsmb.2115]

49 Targetscan miR families [Internet]. Available from: http: //www.targetscan.org/vert\_61/vert\_61\_data\_download/miR\_Family\_Info.txt.zip

50 **John B**, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. *PLoS Biol* 2004; **2**: e363 [PMID: 15502875 DOI: 10.1371/journal.pbio.0020363]

51 **Kertesz M**, Iovino N, Unnerstall U, Gaul U, Segal E. The role of site accessibility in microRNA target recognition. *Nat Genet* 2007; **39**: 1278-1284 [PMID: 17893677 DOI: 10.1038/ng2135]

52 **Kozomara A**, Griffiths-Jones S. miRBase: annotating high confidence microRNAs using deep sequencing data. *Nucleic Acids Res* 2014; **42**: D68-D73 [PMID: 24275495 DOI: 10.1093/nar/gkt1181]

53 PITA FAQs. Segal lab of computational biology [Internet]. Available from: http: //genie.weizmann.ac.il/pubs/mir07/mir07\_notes.html

54 **Stajich JE**, Block D, Boulez K, Brenner SE, Chervitz SA, Dagdigian C, Fuellen G, Gilbert JG, Korf I, Lapp H, Lehväslaiho H, Matsalla C, Mungall CJ, Osborne BI, Pocock MR, Schattner P, Senger M, Stein LD, Stupka E, Wilkinson MD, Birney E. The Bioperl toolkit: Perl modules for the life sciences. *Genome Res* 2002; **12**: 1611-1618 [PMID: 12368254 DOI: 10.1101/gr.361602]

55 **Reddel RR**, Ke Y, Gerwin BI, McMenamin MG, Lechner JF, Su RT, Brash DE, Park JB, Rhim JS, Harris CC. Transformation of human bronchial epithelial cells by infection with SV40 or adenovirus-12 SV40 hybrid virus, or transfection via strontium phosphate coprecipitation with a plasmid containing SV40 early region genes. *Cancer Res* 1988; **48**: 1904-1909 [PMID: 2450641]

56 **Papadopoulos NG**, Papi A, Meyer J, Stanciu LA, Salvi S, Holgate ST, Johnston SL. Rhinovirus infection up-regulates eotaxin and eotaxin-2 expression in bronchial epithelial cells. *Clin Exp Allergy* 2001; **31**: 1060-1066 [PMID: 11467997 DOI: 10.1046/j.1365-2222.2001.01112.x]

57 **Karginov FV**, Conaco C, Xuan Z, Schmidt BH, Parker JS, Mandel G, Hannon GJ. A biochemical approach to identifying microRNA targets. *Proc Natl Acad Sci U S A* 2007; **104**: 19291-19296 [PMID: 18042700 DOI: 10.1073/pnas.0709971104]

58 **Hendrickson DG**, Hogan DJ, Herschlag D, Ferrell JE, Brown PO. Systematic identification of mRNAs recruited to argonaute 2 by specific microRNAs and corresponding changes in transcript abundance. *PLoS One* 2008; **3**: e2126 [PMID: 18461144 DOI: 10.1371/journal.pone.0002126]

59 **Landthaler M**, Gaidatzis D, Rothballer A, Chen PY, Soll SJ, Dinic L, Ojo T, Hafner M, Zavolan M, Tuschl T. Molecular characterization of human Argonaute-containing ribonucleoprotein complexes and their bound target mRNAs. *RNA* 2008; **14**: 2580-2596 [PMID: 18978028 DOI: 10.1261/rna.1351608]

60 **Su H**, Trombly MI, Chen J, Wang X. Essential and overlapping functions for mammalian Argonautes in microRNA silencing. *Genes Dev* 2009; **23**: 304-317 [PMID: 19174539 DOI: 10.1101/gad.1749809]

61 **Dueck A**, Ziegler C, Eichner A, Berezikov E, Meister G. microRNAs associated with the different human Argonaute proteins. *Nucleic Acids Res* 2012; **40**: 9850-9862 [PMID: 22844086 DOI: 10.1093/nar/gks705]

62 **Louafi F**, Martinez-Nunez RT, Sanchez-Elsner T. MicroRNA-155 targets SMAD2 and modulates the response of macrophages to transforming growth factor-{beta}. *J Biol Chem* 2010; **285**: 41328-41336 [PMID: 21036908 DOI: 10.1074/jbc.M110.146852]

63 **Solberg OD**, Ostrin EJ, Love MI, Peng JC, Bhakta NR, Hou L, Nguyen C, Solon M, Nguyen C, Barczak AJ, Zlock LT, Blagev DP, Finkbeiner WE, Ansel KM, Arron JR, Erle DJ, Woodruff PG. Airway epithelial miRNA expression is altered in asthma. *Am J Respir Crit Care Med* 2012; **186**: 965-974 [PMID: 22955319 DOI: 10.1164/rccm.201201-0027OC]

64 **Donnelly RP**, Kotenko SV. Interferon-lambda: a new addition to an old family. *J Interferon Cytokine Res* 2010; **30**: 555-564 [PMID: 20712453 DOI: 10.1089/jir.2010.0078]

65 **Parameswaran P**, Sklan E, Wilkins C, Burgon T, Samuel MA, Lu R, Ansel KM, Heissmeyer V, Einav S, Jackson W, Doukas T, Paranjape S, Polacek C, dos Santos FB, Jalili R, Babrzadeh F, Gharizadeh B, Grimm D, Kay M, Koike S, Sarnow P, Ronaghi M, Ding SW, Harris E, Chow M, Diamond MS, Kirkegaard K, Glenn JS, Fire AZ. Six RNA viruses and forty-one hosts: viral small RNAs and modulation of small RNA repertoires in vertebrate and invertebrate systems. *PLoS Pathog* 2010; **6**: e1000764 [PMID: 20169186 DOI: 10.1371/journal.ppat.1000764]

66 **Jeang KT**. RNAi in the regulation of mammalian viral infections. *BMC Biol* 2012; **10**: 58 [PMID: 22734679 DOI: 10.1186/1741-7007-10-58]

67 **Contoli M**, Message SD, Laza-Stanca V, Edwards MR, Wark PA, Bartlett NW, Kebadze T, Mallia P, Stanciu LA, Parker HL, Slater L, Lewis-Antes A, Kon OM, Holgate ST, Davies DE, Kotenko SV, Papi A, Johnston SL. Role of deficient type III interferon-lambda production in asthma exacerbations. *Nat Med* 2006; **12**: 1023-1026 [PMID: 16906156 DOI: 10.1038/nm1462]

68 **Kuehbacher A**, Urbich C, Zeiher AM, Dimmeler S. Role of Dicer and Drosha for endothelial microRNA expression and angiogenesis. *Circ Res* 2007; **101**: 59-68 [PMID: 17540974 DOI: 10.1161/CIRCRESAHA.107.153916]

69 **Schmitter D**, Filkowski J, Sewer A, Pillai RS, Oakeley EJ, Zavolan M, Svoboda P, Filipowicz W. Effects of Dicer and Argonaute down-regulation on mRNA levels in human HEK293 cells. *Nucleic Acids Res* 2006; **34**: 4801-4815 [PMID: 16971455 DOI: 10.1093/nar/gkl646]

70 **Suárez Y**, Fernández-Hernando C, Pober JS, Sessa WC. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. *Circ Res* 2007; **100**: 1164-1173 [PMID: 17379831 DOI: 10.1161/01.RES.0000265065.26744.17]

71 **Winter J**, Jung S, Keller S, Gregory RI, Diederichs S. Many roads to maturity: microRNA biogenesis pathways and their regulation. *Nat Cell Biol* 2009; **11**: 228-234 [PMID: 19255566 DOI: 10.1038/ncb0309-228]

72 **Yang JS**, Lai EC. Alternative miRNA biogenesis pathways and the interpretation of core miRNA pathway mutants. *Mol Cell* 2011; **43**: 892-903 [PMID: 21925378 DOI: 10.1016/j.molcel.2011.07.024]

73 **Gantier MP**, McCoy CE, Rusinova I, Saulep D, Wang D, Xu D, Irving AT, Behlke MA, Hertzog PJ, Mackay F, Williams BR. Analysis of microRNA turnover in mammalian cells following Dicer1 ablation. *Nucleic Acids Res* 2011; **39**: 5692-5703 [PMID: 21447562 DOI: 10.1093/nar/gkr148]

74 **Adlakha YK**, Saini N. MicroRNA-128 downregulates Bax and induces apoptosis in human embryonic kidney cells. *Cell Mol Life Sci* 2011; **68**: 1415-1428 [PMID: 20924637 DOI: 10.1007/s00018-010-0528-y]

75 **Peruzzi P**, Bronisz A, Nowicki MO, Wang Y, Ogawa D, Price R, Nakano I, Kwon CH, Hayes J, Lawler SE, Ostrowski MC, Chiocca EA, Godlewski J. MicroRNA-128 coordinately targets Polycomb Repressor Complexes in glioma stem cells. *Neuro Oncol* 2013; **15**: 1212-1224 [PMID: 23733246 DOI: 10.1093/neuonc/not055]

76 **Zhang Y**, Chao T, Li R, Liu W, Chen Y, Yan X, Gong Y, Yin B, Liu W, Qiang B, Zhao J, Yuan J, Peng X. MicroRNA-128 inhibits glioma cells proliferation by targeting transcription factor E2F3a. *J Mol Med (Berl)* 2009; **87**: 43-51 [PMID: 18810376 DOI: 10.1007/s00109-008-0403-6]

77 **Weiss GJ**, Bemis LT, Nakajima E, Sugita M, Birks DK, Robinson WA, Varella-Garcia M, Bunn PA, Haney J, Helfrich BA, Kato H, Hirsch FR, Franklin WA. EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines. *Ann Oncol* 2008; **19**: 1053-1059 [PMID: 18304967 DOI: 10.1093/annonc/mdn006]

78 **Schembri F**, Sridhar S, Perdomo C, Gustafson AM, Zhang X, Ergun A, Lu J, Liu G, Zhang X, Bowers J, Vaziri C, Ott K, Sensinger K, Collins JJ, Brody JS, Getts R, Lenburg ME, Spira A. MicroRNAs as modulators of smoking-induced gene expression changes in human airway epithelium. *Proc Natl Acad Sci U S A* 2009; **106**: 2319-2324 [PMID: 19168627 DOI: 10.1073/pnas.0806383106]

79 **Puddicombe SM**, Polosa R, Richter A, Krishna MT, Howarth PH, Holgate ST, Davies DE. Involvement of the epidermal growth factor receptor in epithelial repair in asthma. *FASEB J* 2000; **14**: 1362-1374 [PMID: 10877829 DOI: 10.1096/fj.14.10.1362]

80 **Faraoni I**, Antonetti FR, Cardone J, Bonmassar E. miR-155 gene: a typical multifunctional microRNA. *Biochim Biophys Acta* 2009; **1792**: 497-505 [PMID: 19268705 DOI: 10.1016/j.bbadis.2009.02.013]

81 **Higgs G**, Slack F. The multiple roles of microRNA-155 in oncogenesis. *J Clin Bioinforma* 2013; **3**: 17 [PMID: 24073882 DOI: 10.1186/2043-9113-3-17]

82 **O'Connell RM**, Rao DS, Chaudhuri AA, Boldin MP, Taganov KD, Nicoll J, Paquette RL, Baltimore D. Sustained expression of microRNA-155 in hematopoietic stem cells causes a myeloproliferative disorder. *J Exp Med* 2008; **205**: 585-594 [PMID: 18299402 DOI: 10.1084/jem.20072108]

83 **Dudda JC**, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E, Boudousquie C, Utzschneider DT, Escobar TM, Perret R, Muljo SA, Hebeisen M, Rufer N, Zehn D, Donda A, Restifo NP, Held W, Gattinoni L, Romero P. MicroRNA-155 is required for effector CD8+ T cell responses to virus infection and cancer. *Immunity* 2013; **38**: 742-753 [PMID: 23601686 DOI: 10.1016/j.immuni.2012.12.006]

84 **Vigorito E**, Perks KL, Abreu-Goodger C, Bunting S, Xiang Z, Kohlhaas S, Das PP, Miska EA, Rodriguez A, Bradley A, Smith KG, Rada C, Enright AJ, Toellner KM, Maclennan IC, Turner M. microRNA-155 regulates the generation of immunoglobulin class-switched plasma cells. *Immunity* 2007; **27**: 847-859 [PMID: 18055230 DOI: 10.1016/j.immuni.2007.10.009]

85 **Ceppi M**, Pereira PM, Dunand-Sauthier I, Barras E, Reith W, Santos MA, Pierre P. MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells. *Proc Natl Acad Sci U S A* 2009; **106**: 2735-2740 [PMID: 19193853 DOI: 10.1073/pnas.0811073106]

86 **Wang P**, Hou J, Lin L, Wang C, Liu X, Li D, Ma F, Wang Z, Cao X. Inducible microRNA-155 feedback promotes type I IFN signaling in antiviral innate immunity by targeting suppressor of cytokine signaling 1. *J Immunol* 2010; **185**: 6226-6233 [PMID: 20937844 DOI: 10.4049/jimmunol.1000491]

87 **Pichiorri F**, Suh SS, Ladetto M, Kuehl M, Palumbo T, Drandi D, Taccioli C, Zanesi N, Alder H, Hagan JP, Munker R, Volinia S, Boccadoro M, Garzon R, Palumbo A, Aqeilan RI, Croce CM. MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. *Proc Natl Acad Sci U S A* 2008; **105**: 12885-12890 [PMID: 18728182 DOI: 10.1073/pnas.0806202105]

88 **Jardim MJ**, Dailey L, Silbajoris R, Diaz-Sanchez D. Distinct microRNA expression in human airway cells of asthmatic donors identifies a novel asthma-associated gene. *Am J Respir Cell Mol Biol* 2012; **47**: 536-542 [PMID: 22679274 DOI: 10.1165/rcmb.2011-0160OC]

89 **Martinez-Nunez RT**, Louafi F, Sanchez-Elsner T. The interleukin 13 (IL-13) pathway in human macrophages is modulated by microRNA-155 via direct targeting of interleukin 13 receptor alpha1 (IL13Ralpha1). *J Biol Chem* 2011; **286**: 1786-1794 [PMID: 21097505 DOI: 10.1074/jbc.M110.169367]

90 **Ogawa T**, Iizuka M, Sekiya Y, Yoshizato K, Ikeda K, Kawada N. Suppression of type I collagen production by microRNA-29b in cultured human stellate cells. *Biochem Biophys Res Commun* 2010; **391**: 316-321 [PMID: 19913496 DOI: 10.1016/j.bbrc.2009.11.056]

**P-Reviewer:** Pan Q **S-Editor:** Ji FF **L-Editor: E-Editor:**

**E:\jifangfang\送修稿\2014-7-30\11665\xiuhui\Figures\Figure_1.tif**

**Figure 1** **Prolonged knock-down of DICER is necessary in order to effectively lower the levels of mature microRNAs.** Thirty nmol/L of either anti-DICER or negative control siRNA were used. **A**: Global timeline of the experiment; **B**: DICER mRNA or expression of the indicated microRNAs (miR-30a-5p, -92, -140, 155) was quantified by RT-qPCR. The values plotted represent the mean ± SD, of three independent experiments. For all graphs, unpaired t-test was used to calculate the p values for anti-DICER *vs* negative control siRNA samples; ns: Not significant (*P* > 0.05); a*P* < 0.05; b*P* < 0.01.

E:\jifangfang\送修稿\2014-7-30\11665\xiuhui\Figures\Figure_2.tif

**Figure 2 Prolonged DICER knock-down enhanced human rhinovirus-1B replication (preliminary experiments).** BEAS-2B cells were transfected for three rounds with either a negative control siRNA or anti-DICER siRNA. Forty-eight hours after the third transfection, cells were infected with the indicated amount of HRV-1B, expressed as MOI (multiplicity of infection). RT-qPCR was used to quantify (**A**) DICER mRNA levels before infection or (B-D) HRV-1B RNA at 0, 3 or 8 h post-infection (HPI). The plotted values represent the average of qPCR duplicates from one experiment. The 0 HPI sample at MOI 0.001 was used as calibrator for all samples.

E:\jifangfang\送修稿\2014-7-30\11665\xiuhui\Figures\Figure_3.tif

**Figure 3** **Prolonged DICER knock-down leads to higher levels of viral RNA.** BEAS-2B cells were transfected for three rounds (using 30 nmol/L of siRNA) and then infected with HRV-1B at MOI 0.01. Cells collected just before infection were used to measure DICER mRNA levels (**A**) and miR-30a-5p expression (**B**) by RT-qPCR. HRV-1B RNA (**C**) and IFNB1 mRNA (**D**) levels in infected cells were measured by RT-qPCR at the indicated time points. In (**D**) the time point “-1” refers to uninfected cells, collected just before infection. In (**C**) all the samples were normalised as done for data in Figure 2 [0 h post-infection (HPI), MOI 0.001 sample as calibrator]. Plotted values represent the mean ± SD, of three independent experiments. For all panels, unpaired *t*-test was used to calculate the p values for anti-DICER *vs* negative control siRNA samples; ns: Not significant (*P* > 0.05); a*P* < 0.05; b*P* < 0.01.

**E:\jifangfang\送修稿\2014-7-30\11665\xiuhui\Figures\Figure_4.tif**

**Figure 4 Human rhinovirus-1B RNA co-immunoprecipitates with AGO2 protein in BEAS-2B cells.** **A:** Schematic representation of the rationale behind AGO2 co-IP experiments; **B:** BEAS-2B cells were infected with HRV-1B at MOI 0.01. Six hours post-infection cells were collected and AGO2 co-IP was performed. Plotted values represent the mean ± SD, of three independent experiments. The formula used takes into account the abundance of the RNAs before immunoprecipitation (see materials and methods). Unpaired t-test was used to calculate the p values for AGO2 *vs* IgG control; ns: Not significant (*P* > 0.05); a*P* < 0.05; b*P* < 0.01.

E:\jifangfang\送修稿\2014-7-30\11665\xiuhui\Figures\Figure_5.tif

**Figure 5 Antibody titration for AGO2 co-IP.** These experiments were performed in order to determine the most convenient antibody concentration to use for (**A**) THP-1 (used as additional control) and (**B**) BEAS-2B cells: 1µg was chosen as it would give the highest enrichment of both microRNAs and target mRNAs. These results show that microRNAs are very tightly associated with AGO2 protein, and confirm that microRNA-regulated mRNAs are also considerably co-purified. Previous work from our group has shown that PU.1, SMAD2 and IL13RA1 are targeted by miR-155[45,62,89] while COL1A1 has been shown to be targeted by miR-29b elsewhere[90]. IgG refers to the negative control antibody, AGO2 refers to the anti-AGO2 antibody used. Plotted values represent the average of qPCR duplicates from one experiment.

**E:\jifangfang\送修稿\2014-7-30\11665\xiuhui\Figures\Figure_6.tif**


**Figure 6 Schematic of Targetscan predictions.** Indicated are the target sites predicted for miR-18a, -19b, -106b, -128, -155 on two strains of HRV-A (HRV-1B and -16) and two strains of HRV-B (HRV-14 and -27).

E:\jifangfang\送修稿\2014-7-30\11665\xiuhui\Figures\Figure_7.tif

**Figure 7 Effect of anti-miR transfection on microRNA expression in BEAS-2B cells.** MicroRNA expression was quantified by RT-qPCR 24 h post-transfection with either a negative control anti-miR or the indicated specific anti-miR. Plotted values for miR-18a, -128 and -155 represent the mean±SD of three independent experiments. Unpaired t-test was used to calculate p values for cells transfected with the specific anti-miR *vs* negative control anti-miR; b*P* < 0.01; c*P* < 0.001. The values plotted for miR-106b represent the average of qPCR duplicates from one experiment.

E:\jifangfang\送修稿\2014-7-30\11665\xiuhui\Figures\Figure_8.tif

**Figure 8 Antagonists of miR-155 and miR-128 enhance human rhinovirus-1B replication in BEAS-2B cells.** BEAS-2B cells were transfected with 100 nmol/L of the indicated anti-miR. The following day, cells were infected with HRV-1B (MOI of 0.01). HRV-1B RNA was measured by RT-qPCR from samples collected at 8 h post-infection. Plotted values represent the mean ± SD, from 3 independent experiments. The p values were calculated for each specific anti-miR *vs* the negative control anti-miR, using one way ANOVA with Bonferroni correction; no note: Not significant (*P* > 0.05); a*P* < 0.05; b*P* < 0.01.



**Figure 9 Effect of anti-miR transfection on total cell RNA and GAPDH expression in BEAS-2B cells.** (**A** and **B**) Values obtained for the samples used for Figure 5 or (**C** and **D**) from cells transfected with the indicated anti-miRs but not infected with HRV-1B. The values plotted represent the mean ± SD of three independent experiments. The *P* values were calculated across all the anti-miRs, using one way ANOVA with Bonferroni correction. In **A**, each specific antimiR was significantly different vs negative control (b*P* < 0.01; c*P* < 0.001; d*P* < 0.0001) but not significantly different (ns: *P* > 0.05) to one another.

E:\jifangfang\送修稿\2014-7-30\11665\xiuhui\Figures\Figure_10.tif

**Figure 10 MiR-155 over-expression inhibits human rhinovirus-1B replication.** Lentivirally transduced BEAS-2B cells were infected with human rhinovirus-1B (HRV-1B) at an MOI of 0.01. MiR-155 expression of uninfected cells or HRV-1B RNA (24 h post-infection) was measured by RT-qPCR from three independent experiments. P values for miR-155-overexpressing cells *vs* negative control cells were calculated using the unpaired t-test for miR-155 expression, or the ratio paired t-test for HRV-1B RNA; b*P* < 0.01, c*P* < 0.01.

E:\jifangfang\送修稿\2014-7-30\11665\xiuhui\Figures\Figure_11.tif

**Figure 11 Schematic comparison of microRNA predictions on human rhinovirus-1B.** Indicated are the target sites predicted for miR-18a, -19b, -106b, -128, -155 on HRV-1B by Targetscan, miRanda and PITA algorithms. In addition, the genomic organization and the boundaries of the viral mature proteins are shown.

|  |  |  |
| --- | --- | --- |
| miR name in text | miRBase accession number | mature miR sequence |
| miR-18a | MIMAT0000072 | UAAGGUGCAUCUAGUGCAGAUAG |
| miR-19b | MIMAT0000074 | UGUGCAAAUCCAUGCAAAACUGA |
| miR-106b | MIMAT0000680 | UAAAGUGCUGACAGUGCAGAU |
| miR-128 | MIMAT0000424 | UCACAGUGAACCGGUCUCUUU |
| miR-155 | MIMAT0000646 | UUAAUGCUAAUCGUGAUAGGGGU |

**Table 1 Sequence details of miR-18a, -19b, -106b, -128, -155**

**Table 2 MicroRNAs expressed in healthy primary bronchial epithelial cells**

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| let-7a | miR-149 | miR-218 | miR-345 | miR-501-5p | miR-93 |
| let-7b | miR-152 | miR-221 | miR-34a | miR-502-3p | miR-9 |
| let-7c | miR-155 | miR-222 | miR-34c-5p | miR-502-5p | miR-95 |
| let-7d | miR-15a | miR-223 | miR-361-5p | miR-503 | miR-96 |
| let-7e | miR-15b | miR-22 | miR-362-3p | miR-505 | miR-98 |
| let-7f | miR-16 | miR-224 | miR-362-5p | miR-519a | miR-99a |
| let-7g | miR-17 | miR-23a | miR-365 | miR-523 | miR-99b |
| miR-100 | miR-181a | miR-23b | miR-374a | miR-532-3p |  |
| miR-101 | miR-181c | miR-24 | miR-374b | miR-532-5p |  |
| miR-103 | miR-182 | miR-25 | miR-375 | miR-542-3p |  |
| miR-106a | miR-183 | miR-26a | miR-376a | miR-545 |  |
| miR-106b | miR-184 | miR-26b | miR-376c | miR-548d-5p |  |
| miR-107 | miR-185 | miR-27a | miR-379 | miR-574-3p |  |
| miR-10a | miR-186 | miR-27b | miR-410 | miR-576-3p |  |
| miR-125a-3p | miR-18a | miR-28-3p | miR-411 | miR-579 |  |
| miR-125a-5p | miR-18b | miR-28-5p | miR-422a | miR-582-3p |  |
| miR-125b | miR-191 | miR-296-5p | miR-423-5p | miR-582-5p |  |
| miR-126 | miR-192 | miR-29a | miR-424 | miR-589 |  |
| miR-127-3p | miR-193a-3p | miR-29b | miR-425 | miR-590-5p |  |
| miR-128 | miR-193a-5p | miR-29c | miR-429 | miR-597 |  |
| miR-129-3p | miR-193b | miR-301a | miR-449a | miR-598 |  |
| miR-130a | miR-194 | miR-301b | miR-449b | miR-618 |  |
| miR-130b | miR-195 | miR-30b | miR-450a | miR-625 |  |
| miR-132 | miR-197 | miR-30c | miR-450b-5p | miR-627 |  |
| miR-134 | miR-198 | miR-31 | miR-452 | miR-628-5p |  |
| miR-135a | miR-19a | miR-320 | miR-454 | miR-629 |  |
| miR-135b | miR-19b | miR-323-3p | miR-455-3p | miR-636 |  |
| miR-136 | miR-200a | miR-32 | miR-455-5p | miR-642 |  |
| miR-138 | miR-200b | miR-324-3p | miR-483-5p | miR-652 |  |
| miR-139-5p | miR-200c | miR-324-5p | miR-484 | miR-655 |  |
| miR-140-3p | miR-202 | miR-328 | miR-485-3p | miR-660 |  |
| miR-140-5p | miR-203 | miR-330-3p | miR-486-3p | miR-671-3p |  |
| miR-141 | miR-204 | miR-331-3p | miR-486-5p | miR-708 |  |
| miR-142-3p | miR-205 | miR-331-5p | miR-487a | miR-744 |  |
| miR-145 | miR-20a | miR-335 | miR-489 | miR-758 |  |
| miR-146a | miR-20b | miR-339-3p | miR-491-5p | miR-885-5p |  |
| miR-146b-5p | miR-210 | miR-339-5p | miR-494 | miR-886-3p |  |
| miR-148a | miR-212 | miR-340 | miR-495 | miR-886-5p |  |
| miR-148b | miR-21 | miR-342-3p | miR-500 | miR-92a |  |

Only the miRs with Ct lower than 40 in at least 2 (out of 4) samples of primary bronchial epithelial cells (PBECs) from healthy donors are shown.

**Table 3 Targetscan predictions on human rhinovirus -1B, -16, -14, -27**

| **Virus** | **MiR** | **Site type** | **Site start** | **Site end** | **Context+ score** |  | **Alignment** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **HRV-1B** | 18a | 7mer-1a | 7053 | 7059 | -0.163 | site: | GUGCACUGUAUAUCCCACCUUAU |
|  | |||||| |||||| |
| miR: | GAUAGACGUGAUCUAC---GUGGAAU |
| **HRV-1B** | 128 | 7mer-m8 | 1822 | 1828 | -0.017 | site: | AAACAUUAGUAUGUACACUGUGC |
|  | ||||||| |
| miR: | UUUCUCUGGCCAAGUGACACU |
| **HRV-1B** | 155 | 7mer-m8 | 3716 | 3722 | -0.014 | site: | AUAAAUCCAAUCAAU---AGCAUUAG |
|  | |||| ||||||| |
| miR: | UGGGGAUAGUGCUAAUCGUAAUU |
| **HRV-1B** | 155 | 7mer-m8 | 5998 | 6004 | -0.013 | site: | UGAUUCUAAACCAAUAGCAUUAG |
|  | ||||||| |
| miR: | UGGGGAUAGUGCUAAUCGUAAUU |
| **HRV-1B** | 19b | 8mer-1a | 5088 | 5095 | 0.021 | Site: | UAAUUUACAAAUUGUUUUGCACA |
|  | ||||||| |
| miR: | AGUCAAAACGUACCUAAACGUGU |
| **HRV-1B** | 106b | 7mer-m8 | 5471 | 5477 | 0.025 | Site: | CCAGAAUGUAAUUUAGCACUUUC |
|  | ||||||| |
| miR: | UAGACGUGACAGUCGUGAAAU |
|  |  |  |  |  |  |  |  |
| **HRV-16** | 128 | 7mer-m8 | 3593 | 3599 | -0.04 | Site: | GAUCUUAGACACUUUCACUGUGC |
|  | |||| ||||||| |
| miR: | UUUCUCUGGCCAAGUGACACU |
| **HRV-16** | 155 | 7mer-m8 | 6133 | 6139 | -0.036 | Site: | UUCCAAACUUAAGCUAGCAUUAG |
|  | ||||||| |
| miR: | UGGGGAUAGUGCUAAUCGUAAUU |
| **HRV-16** | 106b | 7mer-1a | 3802 | 3808 | 0.107 | Site: | GCAAACAAUAAUUGCCACUUUAA |
|  | |||||| |
| miR: | UAGACGUGACAGUCGUGAAAU |
|  |  |  |  |  |  |  |  |
| **HRV-14** | 128 | 7mer-1a | 620 | 626 | -0.059 | Site: | CAUAUAUAUACAUAUACUGUGAU |
|  | |||||| |
| miR: | UUUCUCUGGCCAAGUGACACU |
| **HRV-14** | 155 | 7mer-m8 | 6082 | 6088 | -0.056 | Site: | ACUUACACUAAAAGAAGCAUUAU |
|  | ||||||| |
| miR: | UGGGGAUAGUGCUAAUCGUAAUU |
| **HRV-14** | 19b | 7mer-m8 | 5255 | 5261 | -0.001 | Site: | GGACCAAACACAGAAUUUGCACU |
|  | ||||||| |
| miR: | AGUCAAAACGUACCUAAACGUGU |
| **HRV-14** | 106b | 8mer-1a | 2503 | 2510 | 0.047 | Site: | CAGAACUACCUACAUGCACUUUA |
|  | ||||||| |
| miR: | UAGACGUGACAGUCGUGAAAU |
| **HRV-14** | 106b | 7mer-m8 | 4414 | 4420 | 0.057 | Site: | UCCACCAGAUCCCAAGCACUUUG |
|  | ||||||| |
| miR: | UAGACGUGACAGUCGUGAAAU |
|  |  |  |  |  |  |  |  |
|  |  |  |  |  |  |  |  |
| **HRV-27** | 18a | 7mer-1a | 7121 | 7127 | -0.134 | Site: | AGGUUCUUGUGAUACCACCUUAC |
|  | |||||| |
| miR: | GAUAGACGUGAUCUACGUGGAAU |
| **HRV-27** | 19b | 7mer-m8 | 66 | 72 | -0.11 | Site: | CUGGUAUUUUGUACC--UUUGCACG |
|  | ||||| ||||||| |
| miR: | AGUCAAAACGUACCUAAACGUGU |
| **HRV-27** | 128 | 7mer-1a | 619 | 625 | -0.053 | Site: | AUAUAUAGCAUAUAUACUGUGAU |
|  | |||||| |
| miR: | UUUCUCUGGCCAAGUGACACU |
| **HRV-27** | 155 | 7mer-1a | 6152 | 6158 | 0.018 | Site: | CUUAUGUUAGUUUGGGCAUUAAG |
|  | |||||| |
| miR: | UGGGGAUAGUGCUAAUCGUAAUU |
| **HRV-27** | 106b | 8mer-1a | 1193 | 1200 | 0.025 | Site: | CAAAAUUUCACAGUG-GCACUUUA |
|  | ||| ||||||| |
| miR: | UAGACGUGACAGUCGUGAAAU |
| **HRV-27** | 128 | 7mer-1a | 1552 | 1558 | 0.049 | Site: | CCCAGUAUACCUGUU-ACUGUGAC |
|  | ||| |||||| |
| miR: | UUUCUCUGGCCAAGUGACACU |
| **HRV-27** | 19b | 7mer-m8 | 4192 | 4198 | 0.058 | Site: | CAAAUGUCUCAGAAGUUUGCACC |
|  | ||||||| |
| miR: | AGUCAAAACGUACCUAAACGUGU |
| **HRV-27** | 155 | 7mer-m8 | 4632 | 4638 | 0.097 | Site: | UGUGUUGAACCCUGAAGCAUUAG |
|  | ||||||| |
| miR: | UGGGGAUAGUGCUAAUCGUAAUU |

HRV: Human rhinovirus.

**Table 4 MiRanda predictions on human rhinovirus-1B**

| **Virus** | **miR** | **Site start** | **Site end** | **Score** | **Energy (kcal/mol)** |  | **Alignment** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **HRV-1B** | 106b | 2257 | 2276 | 141 | -18.24 | miR: | uaGACGUGACAGUCGUGAAAu |
|  | ||||| ||| || ||||| |
| site: | uuCUGCA-UGUAAGGACUUUu |
| **HRV-1B** | 155 | 3704 | 3723 | 156 | -17.59 | miR: | ugGGGAUAGUGCUAAUCGUAAUu |
|  | :|| |||| | |||||||| |
| site: | aaUCCAAUCA--A-UAGCAUUAg |
| **HRV-1B** | 106b | 5459 | 5478 | 160 | -14.6 | miR: | uagACGUGACAGUCGUGAAAu |
|  | ||:| | |:|||||||| |
| site: | gaaUGUAAU-UUAGCACUUUc |
| **HRV-1B** | 155 | 2878 | 2901 | 144 | -14.2 | miR: | ugGGGAUAGU-GCUAAUCGUAAUu |
|  | |::|| || : ||||||||: |
| site: | cuCUUUACCAUUUCUUAGCAUUGc |
| **HRV-1B** | 155 | 5984 | 6005 | 159 | -13.65 | miR: | ugGGGAUAGUGCUAAUCGUAAUu |
|  | ::||| || | |||||||| |
| Site: | gaUUCUA-AACCAAUAGCAUUAg |
| **HRV-1B** | 128 | 1809 | 1829 | 147 | -13.12 | miR: | uuucucuggcCAAGUGACACu |
|  | || ||||||| |
| Site: | acauuaguauGUACACUGUGc |
| **HRV-1B** | 19b | 5071 | 5095 | 153 | -10.35 | miR: | agucaAAACG--UACCUAAACGUGu |
|  | ||| | || | ||||||| |
| Site: | uguaaUUUACAAAUUGUUUUGCACa |

HRV: Human rhinovirus.

**Table 5 PITA predictions on** human rhinovirus**-1B**

| **Virus** | **miR** | **Site start** | **Site end** | **dG duplex** | **ddG** |  | **Alignment** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **HRV-1B** | 155 | 2901 | 2893 | -15.12 | -11.87 | Site: | UCUUUACCAUUUCUUAGCAUUGCG |
|  | || || ||||||||: |
| miR: | UGGGGAUAGU-GCUAAUCGUAAUU |
| **HRV-1B** | 128 | 1562 | 1554 | -16.4 | -11.11 | Site: | CUAACAUAAGACCAAUCACUGUAUCA |
|  | ||||||| |
| miR: | UUUCUCUGGCCAAGUGACACU |
| **HRV-1B** | 106b | 2276 | 2268 | -17.2 | -10.9 | Site: | GUUUCUGCAUGUAAGGACUUUUG |
|  | ||| || ||||| |
| miR: | UAGACGUGACAGUCGUGAAAU |

The cut off was set at -10 (ddG). HRV: Human rhinovirus.

**Table 6 Full target site list predicted by PITA on human rhinovirus-1B**

| **Virus** | **microRNA** | **Start** | **End** | **dGduplex** | **dGopen** | **ddG** |
| --- | --- | --- | --- | --- | --- | --- |
| **HRV-1B** | miR-155 | 2901 | 2893 | -15.12 | -3.24 | -11.87 |
| **HRV-1B** | miR-128 | 1562 | 1554 | -16.4 | -5.28 | -11.11 |
| **HRV-1B** | miR-106b | 2276 | 2268 | -17.2 | -6.29 | -10.9 |
| **HRV-1B** | miR-18a | 2124 | 2116 | -14.81 | -4.9 | -9.9 |
| **HRV-1B** | miR-106b | 4777 | 4769 | -17.81 | -7.96 | -9.84 |
| **HRV-1B** | miR-19b | 6668 | 6660 | -14.1 | -5.07 | -9.02 |
| **HRV-1B** | miR-18a | 7047 | 7039 | -23.1 | -15.01 | -8.08 |
| **HRV-1B** | miR-155 | 3186 | 3178 | -14.3 | -7.56 | -6.73 |
| **HRV-1B**a | miR-155 | 3723 | 3715 | -14.9 | -8.5 | -6.39 |
| **HRV-1B** | miR-19b | 2016 | 2008 | -12.11 | -5.91 | -6.19 |
| **HRV-1B** | miR-18a | 2570 | 2562 | -16.8 | -11.26 | -5.53 |
| **HRV-1B** | miR-18a | 3108 | 3100 | -13.5 | -8.1 | -5.39 |
| **HRV-1B** | miR-128 | 3609 | 3601 | -11.5 | -6.32 | -5.17 |
| **HRV-1B**a | miR-19b | 5095 | 5088 | -12.53 | -7.64 | -4.88 |
| **HRV-1B**a | miR-106b | 5478 | 5470 | -15.3 | -10.46 | -4.83 |
| **HRV-1B**a | miR-155 | 6005 | 5997 | -11.6 | -7.01 | -4.58 |
| **HRV-1B** | miR-18a | 4144 | 4138 | -12.06 | -7.91 | -4.14 |
| **HRV-1B** | miR-128 | 3513 | 3505 | -14.3 | -10.41 | -3.88 |
| **HRV-1B** | miR-19b | 77 | 70 | -10.42 | -6.61 | -3.8 |
| **HRV-1B** | miR-106b | 5542 | 5534 | -10.6 | -6.95 | -3.64 |
| **HRV-1B** | miR-155 | 5028 | 5020 | -8.1 | -4.94 | -3.15 |
| **HRV-1B** | miR-18a | 4792 | 4784 | -11.5 | -8.37 | -3.12 |
| **HRV-1B** | miR-155 | 3552 | 3544 | -12.6 | -9.54 | -3.05 |
| **HRV-1B** | miR-106b | 3585 | 3577 | -12 | -9.41 | -2.58 |
| **HRV-1B** | miR-18a | 1686 | 1680 | -14.19 | -11.87 | -2.31 |
| **HRV-1B** | miR-106b | 722 | 714 | -4.36 | -2.12 | -2.23 |
| **HRV-1B** | miR-128 | 2562 | 2554 | -14.3 | -12.1 | -2.19 |
| **HRV-1B** | miR-155 | 3975 | 3967 | -13.8 | -11.77 | -2.02 |
| **HRV-1B** | miR-128 | 442 | 434 | -17.2 | -15.21 | -1.98 |
| **HRV-1B** | miR-155 | 6621 | 6613 | -6.5 | -4.56 | -1.93 |
| **HRV-1B** | miR-155 | 4551 | 4543 | -7.3 | -5.68 | -1.61 |
| **HRV-1B** | miR-155 | 5978 | 5970 | -7.9 | -6.41 | -1.48 |
| **HRV-1B** | miR-18a | 1431 | 1423 | -6.6 | -5.13 | -1.46 |
| **HRV-1B** | miR-19b | 3248 | 3240 | -8.71 | -7.66 | -1.04 |
| **HRV-1B** | miR-106b | 6598 | 6590 | -11.8 | -10.94 | -0.85 |
| **HRV-1B**a | miR-128 | 1829 | 1822 | -12.9 | -12.08 | -0.81 |
| **HRV-1B** | miR-155 | 6962 | 6954 | -6 | -5.38 | -0.61 |
| **HRV-1B** | miR-106b | 569 | 563 | -10.2 | -9.77 | -0.42 |
| **HRV-1B** | miR-155 | 870 | 862 | -9.57 | -9.26 | -0.3 |
| **HRV-1B** | miR-18a | 5478 | 5471 | -10.7 | -10.46 | -0.23 |
| **HRV-1B** | miR-155 | 3584 | 3576 | -9.6 | -9.41 | -0.18 |
| **HRV-1B** | miR-155 | 6258 | 6250 | -9.17 | -8.98 | -0.18 |
| **HRV-1B** | miR-19b | 3550 | 3542 | -10.4 | -10.38 | -0.019 |
| **HRV-1B** | miR-106b | 5269 | 5261 | -10 | -10 | 0.0096 |
| **HRV-1B** | miR-106b | 6533 | 6525 | -11.4 | -11.44 | 0.047 |
| **HRV-1B**a | miR-18a | 7059 | 7053 | -18.7 | -19.34 | 0.64 |
| **HRV-1B** | miR-19b | 2309 | 2301 | -6.4 | -7.08 | 0.68 |
| **HRV-1B** | miR-19b | 5076 | 5068 | -9.2 | -10.03 | 0.83 |
| **HRV-1B** | miR-106b | 177 | 169 | -14.3 | -15.51 | 1.21 |
| **HRV-1B** | miR-155 | 624 | 616 | -9.39 | -11.23 | 1.84 |
| **HRV-1B** | miR-106b | 1105 | 1098 | -9.2 | -11.47 | 2.27 |
| **HRV-1B** | miR-155 | 4265 | 4257 | -6.91 | -9.29 | 2.38 |
| **HRV-1B** | miR-155 | 6641 | 6633 | -5.8 | -8.21 | 2.41 |
| **HRV-1B** | miR-18a | 4866 | 4858 | -8.3 | -11.02 | 2.72 |
| **HRV-1B** | miR-18a | 569 | 561 | -7 | -9.77 | 2.77 |
| **HRV-1B** | miR-106b | 6286 | 6278 | -3.51 | -6.53 | 3.02 |
| **HRV-1B** | miR-128 | 6964 | 6956 | -5.69 | -8.77 | 3.08 |
| **HRV-1B** | miR-155 | 2384 | 2376 | -4.1 | -7.44 | 3.34 |
| **HRV-1B** | miR-155 | 234 | 226 | -6.15 | -9.76 | 3.61 |
| **HRV-1B** | miR-19b | 622 | 614 | -7.4 | -11.06 | 3.66 |
| **HRV-1B** | miR-106b | 441 | 435 | -10.5 | -15.27 | 4.77 |
| **HRV-1B** | miR-155 | 6240 | 6232 | -6 | -12.02 | 6.02 |
| **HRV-1B** | miR-106b | 6184 | 6176 | -7.9 | -14.56 | 6.66 |
| **HRV-1B** | miR-106b | 549 | 541 | -6.3 | -15.77 | 9.47 |
| **HRV-1B** | miR-106b | 7007 | 6999 | -7.61 | -18.39 | 10.78 |

aThe sites identified also by Targetscan are highlighted. HRV: Human rhinovirus.